blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3189046

EP3189046 - THERAPEUTIC COMPOUNDS AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  02.07.2021
Database last updated on 11.04.2026
FormerThe patent has been granted
Status updated on  24.07.2020
FormerGrant of patent is intended
Status updated on  09.03.2020
FormerExamination is in progress
Status updated on  16.11.2018
FormerRequest for examination was made
Status updated on  15.06.2017
FormerThe international publication has been made
Status updated on  25.03.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080-4990 / US
For all designated states
Constellation Pharmaceuticals, Inc.
215 First Street, Suite 200
Cambridge, MA 02142 / US
[2017/28]
Inventor(s)01 / ALBRECHT, Brian K.
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
02 / COTE, Alexandre
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
03 / CRAWFORD, Terry
1 DNA Way
South San Francisco, California 94080-4990 / US
04 / DUPLESSIS, Martin
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
05 / GOOD, Andrew Charles
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
06 / LEBLANC, Yves
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
07 / MAGNUSON, Steven
1 DNA Way
South San Francisco, California 94080-4990 / US
08 / NASVESCHUK, Christopher G.
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
09 / PASTOR, Richard
1 DNA Way
South San Francisco, California 94080-4990 / US
10 / ROMERO, F. Anthony
1 DNA Way
South San Francisco, California 94080-4990 / US
11 / TAYLOR, Alexander M.
215 First Street
Suite 200
Cambridge, Massachusetts 02142 / US
 [2017/28]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2020/35]
Former [2017/28]Bailey, Sam Rogerson, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Application number, filing date15763755.402.09.2015
[2017/28]
WO2015US48174
Priority number, dateUS201462046770P05.09.2014         Original published format: US 201462046770 P
[2017/28]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016036873
Date:10.03.2016
Language:EN
[2016/10]
Type: A1 Application with search report 
No.:EP3189046
Date:12.07.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 10.03.2016 takes the place of the publication of the European patent application.
[2017/28]
Type: B1 Patent specification 
No.:EP3189046
Date:26.08.2020
Language:EN
[2020/35]
Search report(s)International search report - published on:EP10.03.2016
ClassificationIPC:C07D403/12, C07D401/04, C07D401/12, C07D403/04, C07D249/12, A61K31/4196, A61P35/00
[2017/28]
CPC:
C07D403/12 (EP,CN,US); A61K31/53 (EP,US); A61K45/06 (US);
A61P35/00 (EP,US); C07D249/12 (EP,US); C07D253/07 (CN);
C07D253/075 (EP,US); C07D401/04 (EP,CN,US); C07D401/12 (EP,CN,US);
C07D403/04 (EP,CN,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/28]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:THERAPEUTISCHE VERBINDUNGEN UND IHRE VERWENDUNG[2017/28]
English:THERAPEUTIC COMPOUNDS AND USES THEREOF[2017/28]
French:COMPOSÉS THÉRAPEUTIQUES ET LEURS UTILISATIONS[2017/28]
Entry into regional phase24.03.2017National basic fee paid 
24.03.2017Designation fee(s) paid 
24.03.2017Examination fee paid 
Examination procedure24.03.2017Examination requested  [2017/28]
24.03.2017Date on which the examining division has become responsible
27.10.2017Amendment by applicant (claims and/or description)
14.11.2018Despatch of a communication from the examining division (Time limit: M04)
20.03.2019Reply to a communication from the examining division
28.06.2019Despatch of a communication from the examining division (Time limit: M04)
05.11.2019Reply to a communication from the examining division
10.03.2020Communication of intention to grant the patent
16.07.2020Fee for grant paid
16.07.2020Fee for publishing/printing paid
16.07.2020Receipt of the translation of the claim(s)
Opposition(s)27.05.2021No opposition filed within time limit [2021/31]
Fees paidRenewal fee
12.09.2017Renewal fee patent year 03
11.09.2018Renewal fee patent year 04
13.09.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU02.09.2015
AL26.08.2020
AT26.08.2020
CY26.08.2020
CZ26.08.2020
DK26.08.2020
EE26.08.2020
ES26.08.2020
FI26.08.2020
HR26.08.2020
IT26.08.2020
LT26.08.2020
LV26.08.2020
MC26.08.2020
MK26.08.2020
MT26.08.2020
NL26.08.2020
PL26.08.2020
RO26.08.2020
RS26.08.2020
SE26.08.2020
SI26.08.2020
SK26.08.2020
SM26.08.2020
TR26.08.2020
IE02.09.2020
LU02.09.2020
BE30.09.2020
BG26.11.2020
NO26.11.2020
GR27.11.2020
IS26.12.2020
PT28.12.2020
[2022/32]
Former [2022/27]HU02.09.2015
AL26.08.2020
AT26.08.2020
CY26.08.2020
CZ26.08.2020
DK26.08.2020
EE26.08.2020
ES26.08.2020
FI26.08.2020
HR26.08.2020
IT26.08.2020
LT26.08.2020
LV26.08.2020
MC26.08.2020
MT26.08.2020
NL26.08.2020
PL26.08.2020
RO26.08.2020
RS26.08.2020
SE26.08.2020
SI26.08.2020
SK26.08.2020
SM26.08.2020
TR26.08.2020
IE02.09.2020
LU02.09.2020
BE30.09.2020
BG26.11.2020
NO26.11.2020
GR27.11.2020
IS26.12.2020
PT28.12.2020
Former [2021/37]AL26.08.2020
AT26.08.2020
CZ26.08.2020
DK26.08.2020
EE26.08.2020
ES26.08.2020
FI26.08.2020
HR26.08.2020
IT26.08.2020
LT26.08.2020
LV26.08.2020
MC26.08.2020
NL26.08.2020
PL26.08.2020
RO26.08.2020
RS26.08.2020
SE26.08.2020
SI26.08.2020
SK26.08.2020
SM26.08.2020
IE02.09.2020
LU02.09.2020
BE30.09.2020
BG26.11.2020
NO26.11.2020
GR27.11.2020
IS26.12.2020
PT28.12.2020
Former [2021/36]AL26.08.2020
AT26.08.2020
CZ26.08.2020
DK26.08.2020
EE26.08.2020
ES26.08.2020
FI26.08.2020
HR26.08.2020
IT26.08.2020
LT26.08.2020
LV26.08.2020
MC26.08.2020
NL26.08.2020
PL26.08.2020
RO26.08.2020
RS26.08.2020
SE26.08.2020
SI26.08.2020
SK26.08.2020
SM26.08.2020
LU02.09.2020
BE30.09.2020
BG26.11.2020
NO26.11.2020
GR27.11.2020
IS26.12.2020
PT28.12.2020
Former [2021/34]AL26.08.2020
AT26.08.2020
CZ26.08.2020
DK26.08.2020
EE26.08.2020
ES26.08.2020
FI26.08.2020
HR26.08.2020
IT26.08.2020
LT26.08.2020
LV26.08.2020
MC26.08.2020
NL26.08.2020
PL26.08.2020
RO26.08.2020
RS26.08.2020
SE26.08.2020
SK26.08.2020
SM26.08.2020
LU02.09.2020
BG26.11.2020
NO26.11.2020
GR27.11.2020
IS26.12.2020
PT28.12.2020
Former [2021/28]AL26.08.2020
AT26.08.2020
CZ26.08.2020
DK26.08.2020
EE26.08.2020
ES26.08.2020
FI26.08.2020
HR26.08.2020
LT26.08.2020
LV26.08.2020
MC26.08.2020
NL26.08.2020
PL26.08.2020
RO26.08.2020
RS26.08.2020
SE26.08.2020
SK26.08.2020
SM26.08.2020
LU02.09.2020
BG26.11.2020
NO26.11.2020
GR27.11.2020
IS26.12.2020
PT28.12.2020
Former [2021/27]AL26.08.2020
AT26.08.2020
CZ26.08.2020
DK26.08.2020
EE26.08.2020
ES26.08.2020
FI26.08.2020
HR26.08.2020
LT26.08.2020
LV26.08.2020
MC26.08.2020
NL26.08.2020
PL26.08.2020
RO26.08.2020
RS26.08.2020
SE26.08.2020
SM26.08.2020
LU02.09.2020
BG26.11.2020
NO26.11.2020
GR27.11.2020
IS26.12.2020
PT28.12.2020
Former [2021/25]AL26.08.2020
AT26.08.2020
CZ26.08.2020
DK26.08.2020
EE26.08.2020
ES26.08.2020
FI26.08.2020
HR26.08.2020
LT26.08.2020
LV26.08.2020
NL26.08.2020
PL26.08.2020
RO26.08.2020
RS26.08.2020
SE26.08.2020
SM26.08.2020
BG26.11.2020
NO26.11.2020
GR27.11.2020
IS26.12.2020
PT28.12.2020
Former [2021/23]AT26.08.2020
CZ26.08.2020
DK26.08.2020
EE26.08.2020
FI26.08.2020
HR26.08.2020
LT26.08.2020
LV26.08.2020
NL26.08.2020
PL26.08.2020
RO26.08.2020
RS26.08.2020
SE26.08.2020
SM26.08.2020
BG26.11.2020
NO26.11.2020
GR27.11.2020
IS26.12.2020
PT28.12.2020
Former [2021/22]CZ26.08.2020
DK26.08.2020
EE26.08.2020
FI26.08.2020
HR26.08.2020
LT26.08.2020
LV26.08.2020
NL26.08.2020
PL26.08.2020
RO26.08.2020
RS26.08.2020
SE26.08.2020
BG26.11.2020
NO26.11.2020
GR27.11.2020
IS26.12.2020
PT28.12.2020
Former [2021/21]DK26.08.2020
FI26.08.2020
HR26.08.2020
LT26.08.2020
LV26.08.2020
NL26.08.2020
PL26.08.2020
RS26.08.2020
SE26.08.2020
BG26.11.2020
NO26.11.2020
GR27.11.2020
IS26.12.2020
PT28.12.2020
Former [2021/12]FI26.08.2020
HR26.08.2020
LT26.08.2020
LV26.08.2020
NL26.08.2020
PL26.08.2020
RS26.08.2020
SE26.08.2020
BG26.11.2020
NO26.11.2020
GR27.11.2020
IS26.12.2020
PT28.12.2020
Former [2021/10]FI26.08.2020
HR26.08.2020
LT26.08.2020
LV26.08.2020
PL26.08.2020
RS26.08.2020
SE26.08.2020
BG26.11.2020
NO26.11.2020
GR27.11.2020
IS26.12.2020
PT28.12.2020
Former [2021/09]FI26.08.2020
LT26.08.2020
SE26.08.2020
BG26.11.2020
NO26.11.2020
GR27.11.2020
PT28.12.2020
Former [2021/08]FI26.08.2020
LT26.08.2020
SE26.08.2020
BG26.11.2020
NO26.11.2020
PT28.12.2020
Former [2021/07]FI26.08.2020
LT26.08.2020
NO26.11.2020
Cited inInternational search[XI] US5591743  (PATOISEAU JEAN-FRANCOIS et al.)
 [XI] WO2011150183  (GE HEALTHCARE LTD et al.)
by applicantUS4943533
 WO9640210
 US5212290
 US5891996
 WO9850433
 US6235883
 EP0659439
 US5616582
 US5457105
 US5475001
 US5654307
 US5679683
 US6084095
 US6265410
 US6455534
 US6521620
 US6596726
 US6713484
 US5770599
 US6140332
 US5866572
 US6399602
 US6344459
 US6602863
 US6391874
 US6344455
 US5760041
 US6002008
 US5747498
 WO9814451
 WO9850038
 WO9909016
 WO9924037
 US5804396
 WO9843960
 WO9738983
 WO9906378
 WO9906396
 WO9630347
 WO9633978
 WO9603397
 WO9633980
   STRUHL K., GENES DEV.,, vol. 12, no. 5, 1989, pages 599 - 606
   JEANMOUGIN F. ET AL., TRENDS BIOCHEM. SCI., vol. 22, no. 5, 1997, pages 151 - 153
   TAMKUN J.W. ET AL., CELL, vol. 7, no. 3, 1992, pages 561 - 572
   PRINJHA ET AL., TRENDS PHARM. SCI., vol. 33, no. 3, 2012, pages 146 - 153
   MULLER, EXPERT REV.,, vol. 13, no. 29, September 2011 (2011-09-01), pages 1 - 20
   JACQUES ET AL.: "Enantiomers, Racemates and Resolutions", 1981, WILEY INTERSCIENCE
   WILEN ET AL., TETRAHEDRON, vol. 33, 1977, pages 2725
   ELIEL, E.L.: "Stereochemistry of Carbon Compounds", 1962, MCGRAW-HILL
   WILEN, S.H.: "Tables of Resolving Agents and Optical Resolutions", 1972, UNIV. OF NOTRE DAME PRESS, pages: 268
   V.T. DEVITA AND S. HELLMAN: "Cancer Principles and Practice of Oncology 6th edition", 15 February 2001, LIPPINCOTT WILLIAMS & WILKINS PUBLISHERS
   ANGEW CHEM. INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186
   JOHNS ET AL., J BIOL. CHEM., vol. 279, no. 29, 2004, pages 30375 - 30384
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.